References
- GoldspielBRClinical overview of the taxanesPharmacotherapy1997175 Pt 2110S125S9322878
- van OosteromATSchrijversDSchrijversDDocetaxel (Taxotere), a review of preclinical and clinical experience. Part II: Clinical experienceAnticancer Drugs1995633563687670133
- CortesJEPazdurRDocetaxelJ Clin Oncol19951310264326557595719
- RingelIHorwitzSBStudies with RP 56976 (taxotere): a semisynthetic analogue of taxolJ Natl Cancer Inst19918342882911671606
- ExtraJMRousseauFBrunoRClavelMLe BailNMartyMPhase I and pharmacokinetic study of Taxotere (RP56976;NSC 628503) given as a short intravenous infusionCancer Res1993535103710428094996
- BissettDSetanoiansACassidyJPhase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusionCancer Res19935335235278093854
- BurrisHIrvinRKuhnJPhase-I clinical-trial of taxotere administered as either a 2-hour or 6-hour intravenous-infusionJ Clin Oncol19931159509588098059
- PazdurRNewmanRANewmanBMPhase I trial of Taxotere: five-day scheduleJ Natl Cancer Inst19928423178117881359154
- TomiakEPiccartMJKergerJPhase-I study of docetaxel administered as a 1-hour intravenous-infusion on a weekly basisJ Clin Oncol1994127145814677912725
- CuiZRYanasarnNSloatBRNanoparticles engineered from lecithin-in- water emulsions as a potential delivery system for docetaxelInt J Pharmaceut20093791174180
- KhalidMNSimardPHoarauDDragomirALerouxJCLong circulating poly(ethylene glycol)-decorated lipid nanocapsules deliver docetaxel to solid tumorsPharm Res200623475275816550475
- XuZChenLGuWThe performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinomaBiomaterials200930222623218851881
- ElsabahyMPerronMEBertrandNYuGELerouxJCSolubilization of docetaxel in poly(ethylene oxide)-block-poly(butylene/styrene oxide) micellesBiomacromolecules2007872250225717579476
- ImmordinoMLBrusaPArpiccoSStellaBDosioFCattelLPreparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxelJ Control Release200391341742912932719
- StraubingerRMBalasubramanianSVPreparation and characterization of taxane-containing liposomesMethods Enzymol20053919711715721376
- IsacchiBArrigucciSMarcaGLConventional and long-circulating liposomes of artemisinin: preparation, characterization, and pharmacokinetic profile in miceJ Liposome Res201121323724421158702
- ColeAJDavidAEWangJGalbanCJHillHLYangVCPolyethylene glycol modified, cross-linked starch-coated iron oxide nanoparticles for enhanced magnetic tumor targetingBiomaterials20113282183219321176955
- KimCKKimJYKimJKParkJSByunYThe use of PEGylated liposomes to prolong circulation lifetimes of tissue plasminogen activatorBiomaterials200930295751575619656559
- ImmordinoMLDosioFCattelLStealth liposomes: review of the basic science, rationale, and clinical applications, existing and potentialInt J Nanomedicine20061329731517717971
- De ValeriolaDBrassinneCGaillardCStudy of excretion balance, metabolism and protein binding of 14C radiolabelled Taxotere (RP56976, NSC628503) in cancer patientsProc Am Cancer Res199334373
- HuynhLLerouxJCAllenCEnhancement of docetaxel solubility via conjugation of formulation-compatible moietiesOrg Biomol Chem20097173437344619675898
- DongXWMattinglyCATsengMChoMAdamsVRMumperRJDevelopment of new lipid-based paclitaxel nanoparticles using sequential simplex optimizationEur J Pharm Biopharm200972191719111929
- AnsellSMJohnstoneSATardiPGModulating the therapeutic activity of nanoparticle delivered paclitaxel by manipulating the hydrophobicity of prodrug conjugatesJ Med Chem200851113288329618465845
- AliSAhmadIPetersAHydrolyzable hydrophobic taxanes: synthesis and anti-cancer activitiesAnticancer Drugs200112211712811261884
- MumperRJDongXWMattinglyCADoxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATPCancer Res20096993918392619383919
- AllenTMCullisPRDrug delivery systems: entering the mainstreamScience200430356651818182215031496
- GardnerSNA mechanistic, predictive model of dose-response curves for cell cycle phase-specific and -nonspecific drugsCancer Res20006051417142510728708
- DeutschHMGlinskiJAHernandezMSynthesis of congeners and prodrugs. 3. Water-soluble prodrugs of taxol with potent antitumor activityJ Med Chem19893247887922564894
- BradleyMOSwindellCSAnthonyFHTumor targeting by conjugation of DHA to paclitaxelJ Control Release2001741–323323611489499